All In Biotech

BLA 020378 · Emd Serono

Gonal-F

Follitropin Alfa/Beta · Subcutaneous

Orphan

Last checked: Nov 20, 2026Latest source record: Nov 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Sep 29, 1997

Approved uses

2

Original approval plus efficacy supplements

Registered trials

62

13 Phase 3, 3 recruiting

FAERS reports

2,046

1,696 serious, 32 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 2, 2025.

GONAL-f is indicated for: GONAL-f is a gonadotropin indicated for: Women: Induction of ovulation and pregnancy in oligo-anovulatory infertile women for whom the cause of infertility is functional and not due to primary ovarian failure. ( 1.1 ) Development of multiple follicles in ovulatory infertile women as part of Assisted Reproductive Technology (ART) cycles. ( 1.2 ) Men: Induction of spermatogenesis in infertile men with primary and secondary hypogonadotropic hypogonadism for whom the cause of infertility is not due to primary testicular failure. ( 1.3 ) 1.1 Induction of ovulation and pregnancy in oligo-anovulatory infertile women for whom the cause of infertility is functional and not due to primary ovarian failure. 1.2 Development of multiple follicles in ovulatory infertile women as part of an assisted reproductive technology (ART) cycle. 1.3 Induction of spermatogenesis in infertile men with primary and secondary hypogonadotropic hypogonadism for whom the cause of infertility is not due to primary testicular failure.

Mechanism: GONAL-f stimulates ovarian follicular growth in women who do not have primary ovarian failure. In order to bring about final maturation of the follicle and ovulation in the absence of an endogenous LH surge, human chorionic gonadotropin (hCG) must be given, following the administration of GONAL-f, when monitoring of the patient indicates that sufficient follicular development is achieved. GONAL-f stimulates spermatogenesis in men with hypogonadotropic hypogonadism when administered with hCG.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 24, 2000 Supplement 6 · Efficacy LabelLetter
  • Sep 29, 1997 Original approval · Type 3 - New Dosage Form
5 products under this application
  • GONAL-F · FOLLITROPIN ALFA/BETA 150 IU/VIAL · INJECTABLE, SUBCUTANEOUS · Discontinued
  • GONAL-F · FOLLITROPIN ALFA/BETA 450 IU/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription
  • GONAL-F · FOLLITROPIN ALFA/BETA 37.5 IU/VIAL · INJECTABLE, SUBCUTANEOUS · Discontinued
  • GONAL-F · FOLLITROPIN ALFA/BETA 75 IU/VIAL · INJECTABLE, SUBCUTANEOUS · Discontinued
  • GONAL-F · FOLLITROPIN ALFA/BETA 1,050 IU/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Follitropin Alfa/Beta" as an intervention, any sponsor and status, largest first.

All 62 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ovarian hyperstimulation syndrome696
  • ascites223
  • abdominal pain130
  • abortion spontaneous123
  • abdominal distension120
  • nausea104
  • dyspnoea100
  • vomiting85
  • inappropriate schedule of drug administration80
  • drug ineffective78
  • pleural effusion76
  • off label use75

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200415
200521
200618
200745
200843
200944
201054
201165
201279
2013109
2014139
2015114
2016102
2017174
2018110
2019165
2020116
202145
2022127
2023143
2024129
2025100
202689

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 66 on PubMed

Sponsor: Emd Serono

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.